$HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Jeffrey Dayno
CEO
268
Employees
$27.72
Current Price
$2.22B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $139,171.39 | 3,746 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $892,004.57 | 24,707 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jan 26, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale | 3,746 | $37.15 | $139,171.39 | View Details |
| Jan 15, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale | 20,961 | $35.92 | $752,833.18 | View Details |
7 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated$0.84
ActualN/A
Revenue
Estimated$240.32M
ActualN/A